Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
- 4 November 1972
- journal article
- Vol. 107 (9) , 851-5
Abstract
High-dose intermittent cyclophosphamide was used in the treatment of 19 patients with plasma cell myeloma who had demonstrated resistance to melphalan. Good objective improvement was found in six patients and partial responses in five. Patients have survived from three to more than 36 months (estimated median 21 months) after starting cyclophosphamide, and 11 are still alive. The important implications of the lack of cross-resistance between these two alkylating agents are discussed in terms of the mechanisms of cellular resistance to alkylating agents.This publication has 13 references indexed in Scilit:
- Transport of Nitrogen Mustard on the Transport-Carrier for Choline in L5178Y LymphoblastsScience, 1971
- Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and -resistant L5178Y lymphoblasts.1970
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969
- Differences in the in vivo alkylation and cross-linking of nitrogen mustard-sensitive and -resistant lines of Lettré-Ehrlich asites tumors.1969
- Repair of Alkylated DNA in Mammalian CellsNature, 1968
- The Treatment of Plasma Cell MyelomaAdvances in Cancer Research, 1967
- MULTIPLE MYELOMA - .2. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS1964
- Tumour sulphydryl levels and sensitivity to the nitrogen mustard merophanBiochemical Pharmacology, 1963
- Non-Protein Sulphydryl Group in the Original Strain and Sub-line of the Ascites Tumour resistant to Alkylating ReagentsNature, 1960
- Maximum utilization of the life table method in analyzing survivalJournal of Chronic Diseases, 1958